Companies › PPD Development, LP
3 active drug programs in 6 registered trials: 6 Phase 2; Respiratory; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| bevacizumab Vascular endothelial growth factor A inhibitor | VEGFA | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
| paridiprubart CD11b/CD18 integrin antagonist | ITGAM | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
| vilobelimab Complement C5 inhibitor | C5 | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06701656 | bevacizumab | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
| NCT06703073 | bevacizumab | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
| NCT06701682 | vilobelimab | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
| NCT06703073 | vilobelimab | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
| NCT06703073 | paridiprubart | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
| NCT06701669 | paridiprubart | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | Respiratory | Jul 2028 |
Connect Biopharm Aqualung Therapeutics Upstream Bio Shanghai Mabgeek Biotech.Co.Ltd Uniquity One (UNI)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.